Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle‐controlled study

Rui-fen, Liu; Wu, Xiao‐Xuan; Wang, Xiao; Gao, Jing; Zhou, Jun; Zhao, Qi

doi:10.1002/alr.21882

Cited by 10 publications

(4 citation statements)

References 29 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The eye rubbing frequency was assessed on a scale ranging from 1 to 5, where 1 represents no eye rubbing, and 5 represents constant eye rubbing [ 3 , 21 ]. Signs of conjunctival hyperemia, swelling, papillae, and corneal epithelial disorder were assessed and graded by severity from 0 (no corresponding signs) to 3 (serious signs) by the clinician [ 22 – 24 ].…”

Section: Methodsmentioning

confidence: 99%

Corneal biomechanical changes in allergic conjunctivitis

Wang

Deng

et al. 2021

Eye and Vis

View full text Add to dashboard Cite

Background To explore corneal biomechanical changes, identify related factors and determine early indicators of keratoconus (KC) development risk in allergic conjunctivitis (AC) patients. Methods A total of 50 patients, including 20 eyes without AC and 30 eyes with AC were enrolled in this study. All patients underwent a complete ocular examination, including evaluations of clinical manifestations of AC, corneal tomography and densitometry by Pentacam, corneal biomechanics by Corvis ST, and corneal and epithelial thickness mapping by RTvue optical coherence tomography (OCT). Results The index of surface variance (ISV), index of vertical asymmetry (IVA), keratoconus index (KI), index of height decentration (IHD) and Belin/Ambrosio enhanced ectasia total deviation index (BAD-D) were significantly higher in the AC group than in the non-allergic conjunctivitis (NAC) group (P < 0.05). The tomography and biomechanical index (TBI) was also significantly higher in the AC group (P = 0.04). The average epithelial thickness in the 2–7 mm annulus was significantly thinner in the AC group than in the NAC group (P < 0.05). The average densitometry of the total cornea and the anterior layer were higher in the AC group than in the NAC group (P < 0.001). The ISV, IVA, KI, IHD and BAD-D were significantly correlated with the TBI and changes in corneal epithelial thickness in AC patients (P < 0.05). The changes in epithelial thickness were closely related to the eye rubbing frequency and allergic sign scores (P < 0.05). Conclusions AC patients should be advised to routinely undergo corneal tomographic and biomechanical measurements, and the TBI could be used as an indicator of KC development risk in AC patients. Trial registration Corneal Biomechanical Changes of Allergic Conjunctivitis, NCT04299399. Registered March 3, 2020 - Retrospectively registered.

show abstract

Section: Methodsmentioning

confidence: 99%

Corneal biomechanical changes in allergic conjunctivitis

Wang

Deng

et al. 2021

Eye and Vis

View full text Add to dashboard Cite

show abstract

“…There were no clinically significant increases from baseline in IOP (≥10 mm Hg). In the other active-comparator study (also investigator-masked), Chinese children (ages 5-10 years) with SAC were randomized to bilateral treatment with olopatadine hydrochloride 0.1% twice a day (BID), emedastine difumarate 0.05% BID, LE 0.5% QID, or artificial tears (AT) for 14 ± 2 days [31]. On both days 8 and 15, all active treatments were found to be more effective than AT (P < 0.05) in reducing signs (conjunctival papillae, follicle, conjunctival congestion, edema) and symptoms (itching, photophobia, blinking) of SAC.…”

Section: Seasonal Allergic Conjunctivitismentioning

confidence: 99%

Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid

Comstock¹,

Sheppard

2018

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Topical corticosteroids are an important pharmacotherapy for the management of various inflammatory conditions affecting the anterior segment of the eye. However, medications in this class are associated with well-known risks including increased intraocular pressure (IOP) and development of cataracts. The topical corticosteroid loteprednol etabonate (LE) was developed with the specific intention of minimizing these side effects. Areas covered: The focus of this review is to examine published efficacy and safety data for LE, a drug engineered to undergo rapid metabolism to inactive metabolites with the goal of improved safety. Two decades of clinical research focused on LE formulations are reviewed, including the use of LE in combination with tobramycin. The cumulative body of experience affirms the concept that the molecular design of LE confers certain safety benefits without compromising the desired anti-inflammatory efficacy of a topical corticosteroid. Expert opinion: Loteprednol etabonate is a mainstay for topical therapy of a wide variety of commonplace and niche conditions of the ocular surface and the anterior segment, including in the healing post-operative patient. Its versatility and safety allow eye care providers to recommend both acute induction as well as chronic maintenance therapy with appropriate follow-up.

show abstract

“…Allergic conjunctivitis causes severe ocular discomfort, significantly reducing the quality of life in patients. Since allergic conjunctivitis is a chronic condition, it also has serious economic effects [11].…”

Section: Discussionmentioning

confidence: 99%

The Effect Of Topical Antihistamines Used Single Dose Daily in Allergic Conjunctivitis

Erdoğan¹,

Cam²

2018

TOOPHTJ

View full text Add to dashboard Cite

Background and Objective: To evaluate the efficacy of 0.2% olopatadine and to compare olopatadine 0.1%, ketotifen 0.025% and emadastine 0.05% in the treatment of allergic conjunctivitis. Methods: In this retrospectively designed study, we investigated the files of patients who had been diagnosed with perineal or seasonal allergic conjunctivitis in the teaching hospital of Maltepe University between April 2017 and July 2017. We divided the patients into four groups. The patients in each group had similar symptoms and scores before medication. The first, second, third and fourth groups were prescribed olapatadine 0.1%, olopatadine 0.2%, ketotifen 0.025% and emedastine 0.05%, respectively. We evaluated the symptoms and signs of the patients on the 15th day after treatment, and compared the results between the groups. Results: We investigated the files of 80 patients. There were 20 patients in each group. We evaluated the symptoms and finding scores after treatment. The symptoms and findings of allergic conjunctivitis had improved in all the four groups. There was no difference in the treatment responses between the four groups. Conclusion: Olopatadine 0.2%, olopatadine 0.1%, ketotifen 0.025% and emedastine 0.05% were all equally effective in improving the signs and symptoms of allergic conjunctivitis.

show abstract

Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle‐controlled study

Cited by 10 publications

References 29 publications

Corneal biomechanical changes in allergic conjunctivitis

Corneal biomechanical changes in allergic conjunctivitis

Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid

The Effect Of Topical Antihistamines Used Single Dose Daily in Allergic Conjunctivitis

Contact Info

Product

Resources

About